A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results

Abstract

The data presented here indicate that the provision to patients with knee OA of viscosupplementation with hylan G-F 20 within an appropriate care treatment regimen provides benefits in the knee, overall health and health related quality of life at reduced levels of co-therapy and systemic adverse reactions.

The effectiveness of pulsed electrical stimulation in the management of osteoarthritis of the knee: Results of a double‐blind, randomized, placebo‐controlled, repeated‐measures trial

“…A priori calculations for sample size were based on reported VAS pain score (6), patient's global assessment of disease activity (6), and WOMAC function score (27) data.…”

Rheologic Behavior of Osteoarthritic Synovial Fluid after Addition of Hyaluronic Acid: A Pilot Study

“…The injection of very high-molecular-weight HA, and especially of partially cross-linked HA, may allow recovery of desirable viscoelastic behavior (especially elastic contribution) [7,36,37]. Other biologic roles for exogenous HA in OA include an analgesic effect by interaction with pain receptors [23], promotion of endogenous HA production [4,38], and various antiinflammatory effects [10,15,24,34,42,43,56]. Nevertheless, the biologic effects of VS last much longer than its presence in SF, leading to the concept of ''viscoinduction'' effects extending beyond the effects of viscosupplementation.…”

Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study

“…Controlled studies versus placebo have shown that hylan G-F 20, a cross-linked high MW derivative of HA, can decrease pain and improve joint mobility in patients suVering from knee OA [1,10,13,18,20,26]. After 3 £ 2 mL intraarticular injections administered 1 week apart, peak eYcacy occurs between 8 and 12 weeks after the administration of the Wrst injection, and can last for up to 12 months [18].…”

“…After 3 £ 2 mL intraarticular injections administered 1 week apart, peak eYcacy occurs between 8 and 12 weeks after the administration of the Wrst injection, and can last for up to 12 months [18]. This regimen was established as being clinically superior to a regimen of 2 £ 2 mL administered 2 weeks apart [20].…”